Key result
Newer anticoagulant agents provide an alternative to warfarin for stroke prevention in non-valvular atrial fibrillation, eliminating the need for frequent monitoring.
Why the study?
Do newer anticoagulants prevent stroke and systemic embolism in persons with non-valvular atrial fibrillation?
Do newer anticoagulants prevent stroke and systemic embolism in persons with non-valvular atrial fibrillation?
This article reviews the use of warfarin and newly approved novel anticoagulants for stroke prevention in non-valvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
May reduce monitoring burden for eligible non-valvular AF patients; leaves open optimal agent selection and long-term comparative data.
Harburger et al. (2012) conducted a review in Non-valvular atrial fibrillation. Newer anticoagulants vs. Warfarin was evaluated. Newer anticoagulant agents provide an alternative to warfarin for stroke prevention in non-valvular atrial fibrillation, eliminating the need for frequent monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: